Prescient Therapeutics Ltd has released a press release.
PTX Broker Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Earlier from Prescient Therapeutics
- European Patent Granted for PTX-200
- Kansas University Joins PTXs AML Trial
- FDA Grants Orphan Drug Designation for PTX-200 in AML
- March 2017 Appendix 4C - Quarterly
- Successful Completion of Phase 1b Breast Cancer Trial
Later from Prescient Therapeutics
- Clinical Trial Update
- Novel PTX-100 Cancer Approach Published in Nature
- June 2017 Appendix 4C - Quarterly
- Appendix 4E and 2017 Annual Report
- Prescient to resume AML trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics